DC-based immunotherapy of B-cell malignancies.
B-cell malignancies are a group of diseases for which vaccination protocols have been thoroughly studied over the last few years. All different vaccination protocols share the goal of inducing or augmenting tumor-specific immune responses in the tumor-bearing host, in order to potentially achieve therapeutic benefit in these otherwise ultimately fatal diseases. Attention has been drawn to the use of DC-based immunotherapy protocols relying on the unique properties of these powerful APCs. This review focuses on DC-based immunotherapy experience gained so far in B-cell malignancies, and discusses published and on-going clinical trials in follicular NHL and multiple myeloma, and preclinical results in CLL and Waldenström's macroglobulinemia. This will form the basis for a discussion of perspectives of DC vaccination in this group of human malignancies.
Department of Hematology, Oncology, Immunology and Rheumatology, University of Tübingen, Tübingen, Germany.
V L
VL
Reichardt
Peter
P
Brossart
D001402:B-Lymphocytes / Q000473:pathology*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy; D008224:Lymphoma, Follicular / Q000628:therapy; D009101:Multiple Myeloma / Q000628:therapy; D008258:Waldenstrom Macroglobulinemia / Q000628:therapy
D019496:Cancer Vaccines